375 related articles for article (PubMed ID: 32241924)
1. Structural basis for allosteric PARP-1 retention on DNA breaks.
Zandarashvili L; Langelier MF; Velagapudi UK; Hancock MA; Steffen JD; Billur R; Hannan ZM; Wicks AJ; Krastev DB; Pettitt SJ; Lord CJ; Talele TT; Pascal JM; Black BE
Science; 2020 Apr; 368(6486):. PubMed ID: 32241924
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Hopkins TA; Shi Y; Rodriguez LE; Solomon LR; Donawho CK; DiGiammarino EL; Panchal SC; Wilsbacher JL; Gao W; Olson AM; Stolarik DF; Osterling DJ; Johnson EF; Maag D
Mol Cancer Res; 2015 Nov; 13(11):1465-77. PubMed ID: 26217019
[TBL] [Abstract][Full Text] [Related]
3. Novel modifications of PARP inhibitor veliparib increase PARP1 binding to DNA breaks.
Velagapudi UK; Rouleau-Turcotte É; Billur R; Shao X; Patil M; Black BE; Pascal JM; Talele TT
Biochem J; 2024 Mar; 481(6):437-460. PubMed ID: 38372302
[TBL] [Abstract][Full Text] [Related]
4. Clinical PARP inhibitors allosterically induce PARP2 retention on DNA.
Langelier MF; Lin X; Zha S; Pascal JM
Sci Adv; 2023 Mar; 9(12):eadf7175. PubMed ID: 36961901
[TBL] [Abstract][Full Text] [Related]
5. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling.
van Beek L; McClay É; Patel S; Schimpl M; Spagnolo L; Maia de Oliveira T
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34066057
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition.
Ogden TEH; Yang JC; Schimpl M; Easton LE; Underwood E; Rawlins PB; McCauley MM; Langelier MF; Pascal JM; Embrey KJ; Neuhaus D
Nucleic Acids Res; 2021 Feb; 49(4):2266-2288. PubMed ID: 33511412
[TBL] [Abstract][Full Text] [Related]
7. ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification.
Rouleau-Turcotte É; Pascal JM
J Biol Chem; 2023 Dec; 299(12):105397. PubMed ID: 37898399
[TBL] [Abstract][Full Text] [Related]
8. Rapid Detection and Signaling of DNA Damage by PARP-1.
Pandey N; Black BE
Trends Biochem Sci; 2021 Sep; 46(9):744-757. PubMed ID: 33674152
[TBL] [Abstract][Full Text] [Related]
9. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors.
Thorsell AG; Ekblad T; Karlberg T; Löw M; Pinto AF; Trésaugues L; Moche M; Cohen MS; Schüler H
J Med Chem; 2017 Feb; 60(4):1262-1271. PubMed ID: 28001384
[TBL] [Abstract][Full Text] [Related]
10. Differential anti-proliferative activities of poly(ADP-ribose) polymerase (PARP) inhibitors in triple-negative breast cancer cells.
Chuang HC; Kapuriya N; Kulp SK; Chen CS; Shapiro CL
Breast Cancer Res Treat; 2012 Jul; 134(2):649-59. PubMed ID: 22678161
[TBL] [Abstract][Full Text] [Related]
11. Enhancement of Soft Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1 Inhibitors.
Mangoni M; Sottili M; Salvatore G; Meattini I; Desideri I; Greto D; Loi M; Becherini C; Garlatti P; Delli Paoli C; Dominici L; Gerini C; Scoccianti S; Bonomo P; Silvano A; Beltrami G; Campanacci D; Livi L
Radiat Res; 2018 Nov; 190(5):464-472. PubMed ID: 30067444
[TBL] [Abstract][Full Text] [Related]
12. Examination of Diazaspiro Cores as Piperazine Bioisosteres in the Olaparib Framework Shows Reduced DNA Damage and Cytotoxicity.
Reilly SW; Puentes LN; Wilson K; Hsieh CJ; Weng CC; Makvandi M; Mach RH
J Med Chem; 2018 Jun; 61(12):5367-5379. PubMed ID: 29856625
[TBL] [Abstract][Full Text] [Related]
13. PARP-DNA trapping ability of PARP inhibitors jeopardizes astrocyte viability: Implications for CNS disease therapeutics.
Sinha A; Katyal S; Kauppinen TM
Neuropharmacology; 2021 Apr; 187():108502. PubMed ID: 33631119
[TBL] [Abstract][Full Text] [Related]
14. The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency.
Gatti M; Imhof R; Huang Q; Baudis M; Altmeyer M
Cell Rep; 2020 Aug; 32(5):107985. PubMed ID: 32755579
[TBL] [Abstract][Full Text] [Related]
15. Contrasting sirtuin and poly(ADP-ribose)polymerase activities of selected 2,4,6-trisubstituted benzimidazoles.
Yeong KY; Tan SC; Mai CW; Leong CO; Chung FF; Lee YK; Chee CF; Abdul Rahman N
Chem Biol Drug Des; 2018 Jan; 91(1):213-219. PubMed ID: 28719017
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
Rajawat J; Shukla N; Mishra DP
Med Res Rev; 2017 Nov; 37(6):1461-1491. PubMed ID: 28510338
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a Low-Toxicity PARP Inhibitor as a Neuroprotective Agent for Parkinson's Disease.
Puentes LN; Lengyel-Zhand Z; Reilly SW; Mach RH
Mol Neurobiol; 2021 Aug; 58(8):3641-3652. PubMed ID: 33788167
[TBL] [Abstract][Full Text] [Related]
18. The Oncogenic Helicase ALC1 Regulates PARP Inhibitor Potency by Trapping PARP2 at DNA Breaks.
Blessing C; Mandemaker IK; Gonzalez-Leal C; Preisser J; Schomburg A; Ladurner AG
Mol Cell; 2020 Dec; 80(5):862-875.e6. PubMed ID: 33275888
[TBL] [Abstract][Full Text] [Related]
19. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response.
Kim C; Wang XD; Yu Y
Elife; 2020 Aug; 9():. PubMed ID: 32844745
[TBL] [Abstract][Full Text] [Related]
20. Molecular Mechanisms of PARP-1 Inhibitor 7-Methylguanine.
Nilov D; Maluchenko N; Kurgina T; Pushkarev S; Lys A; Kutuzov M; Gerasimova N; Feofanov A; Švedas V; Lavrik O; Studitsky VM
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32245127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
